Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Bevacizumab is the only therapeutic target approved for patients with persistent, recurrent or advanced cervical cancer from a phase III study that combined with chemotherapy; it proves a significant increase in overall survival. To retrospectively assess the efficacy and safety of bevacizumab as the first-line treatment in patients from usual clinical practice with recurrent/persistent or advanced cervical cancer.

Patients and methods

Treatment consisted of cisplatin 50 mg/m2 or carboplatin AUC 5 plus paclitaxel 175 mg/m2 for 6–8 cycles and bevacizumab 15 mg/kg every 3 weeks up to progression or unacceptable toxicity. The endpoints were progression-free survival (PFS), overall survival (OS), response rates (RR) and toxicity.

Results

Twenty-seven patients were included from January 2014 to June 2017, with a median follow-up 10, 1 months. Eleven percent had recurrent/persistent disease and 89% had metastatic disease at diagnosis. The prior exposition to platinum was 70%. The median PFS and OS were 9, 6 and 21, 5 months, respectively. There was an increase of fistula formation (22%). All of them had pelvic and peritoneal disease at the beginning of treatment and previous treatment with chemoradiotherapy; non-incidence differences were found according to the type of platinum agent used. There were two treatment-related deaths, one from intestinal perforation and another from severe sepsis.

Conclusion

Finally, although our study does have certain limitations, we believe that it can provide useful information and encouraging evidence that the routine use of bevacizumab as part of first-line treatment of patients with advanced cervical cancer may be associated with outcomes comparable with those obtained in GOG240 study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Thigpen T, Shingleton H, Homesley H, et al. cis-Dichlorodiammineplatinum (II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep. 1979;63:1549–55.

    PubMed  CAS  Google Scholar 

  2. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113–9.

    Article  PubMed  CAS  Google Scholar 

  3. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626–33.

    Article  PubMed  CAS  Google Scholar 

  4. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103(2):489–93.

    Article  PubMed  CAS  Google Scholar 

  6. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2009;27(7):1069–74.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013;130:64–8.

    Article  PubMed  CAS  Google Scholar 

  8. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Tewari KS, Sill MW, Penson RT, et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: a NRG Oncology-Gynecologic Oncology Group study. Madrid, Spain: Proffered Paper Session presented at European Society for Medical Oncology; 28 Sept 2014.

  10. Minion LE, Bai J, Monk BJ, Robin Keller L, et al. A markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol. 2015;137(3):490–6. https://doi.org/10.1016/j.ygyno.2015.02.027.

    Article  PubMed  CAS  Google Scholar 

  11. Parkinson B, Viney R, Haas M, et al. Real-world evidence: a comparison of the Australian herceptin program and clinical trials of trastuzumab for HER2-positive metastatic breast cancer. Pharmacoeconomics. 2016;34(10):1039–50. https://doi.org/10.1007/s40273-016-0411-2.).

    Article  PubMed  Google Scholar 

  12. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1(1):e9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93.

    Article  PubMed  Google Scholar 

  14. Garrison LP Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326–35.

    Article  PubMed  Google Scholar 

  15. Annemans L, Aristides M, Kubin M. Real-life data: a growing need. ISPOR Connect. 2007;13(5):8–12.

    Google Scholar 

  16. Haemmerle M, Bottsford-Miller J, Pradeep S, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016;126(5):1885–96. https://doi.org/10.1172/JCI85086 (Epub 2016 Apr 11).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Tewari KS, Sill MW, Penson RP, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–63.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116:44–9.

    Article  PubMed  CAS  Google Scholar 

  19. Tewari KS, Sill MW, Monk BJ, et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with and without bevacizumab: a NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2015;21:5480–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Av. Carlos Haya s/n, 29010, Málaga, Spain

    A. Godoy-Ortiz, A. Galeote, B. Pajares, E. Saez, E. Alba & A. Sánchez-Muñoz

  2. Department of Oncology, Complejo Hospitalario de Jaén, Jaén, Spain

    Y. Plata

  3. Medical Oncology Service, Hospital Costa del Sol, Málaga, Marbella, Spain

    J. Alcaide

  4. Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain

    B. Pajares, E. Alba & A. Sánchez-Muñoz

  5. Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain

    E. Alba

Authors
  1. A. Godoy-Ortiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Plata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Alcaide
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Galeote
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Pajares
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Saez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Alba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Sánchez-Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Godoy-Ortiz.

Ethics declarations

Conflict of interest

The authors declare that they have no potential conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Godoy-Ortiz, A., Plata, Y., Alcaide, J. et al. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients. Clin Transl Oncol 20, 922–927 (2018). https://doi.org/10.1007/s12094-017-1808-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1808-x

Keywords

Search

Navigation